JP2008520242A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2008520242A5 JP2008520242A5 JP2007543226A JP2007543226A JP2008520242A5 JP 2008520242 A5 JP2008520242 A5 JP 2008520242A5 JP 2007543226 A JP2007543226 A JP 2007543226A JP 2007543226 A JP2007543226 A JP 2007543226A JP 2008520242 A5 JP2008520242 A5 JP 2008520242A5
- Authority
- JP
- Japan
- Prior art keywords
- age
- macular degeneration
- related macular
- cfh
- polynucleotide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 206010064930 age-related macular degeneration Diseases 0.000 claims 51
- 208000002780 macular degeneration Diseases 0.000 claims 51
- 101150030967 CFH gene Proteins 0.000 claims 39
- 108091033319 polynucleotide Proteins 0.000 claims 39
- 102000040430 polynucleotide Human genes 0.000 claims 39
- 239000002157 polynucleotide Substances 0.000 claims 39
- 239000000523 sample Substances 0.000 claims 39
- 102100035432 Complement factor H Human genes 0.000 claims 32
- 239000013615 primer Substances 0.000 claims 25
- 239000000203 mixture Substances 0.000 claims 22
- 125000003729 nucleotide group Chemical group 0.000 claims 20
- 238000009396 hybridization Methods 0.000 claims 15
- 229920001184 polypeptide Polymers 0.000 claims 15
- 102000004196 processed proteins & peptides Human genes 0.000 claims 15
- 108090000765 processed proteins & peptides Proteins 0.000 claims 15
- 239000002773 nucleotide Substances 0.000 claims 14
- 238000000034 method Methods 0.000 claims 11
- 108020004999 messenger RNA Proteins 0.000 claims 10
- 150000001413 amino acids Chemical class 0.000 claims 8
- 239000003814 drug Substances 0.000 claims 7
- 239000003937 drug carrier Substances 0.000 claims 7
- 238000004519 manufacturing process Methods 0.000 claims 7
- 102000039446 nucleic acids Human genes 0.000 claims 6
- 108020004707 nucleic acids Proteins 0.000 claims 6
- 150000007523 nucleic acids Chemical class 0.000 claims 6
- 238000009007 Diagnostic Kit Methods 0.000 claims 5
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 claims 5
- 125000000487 histidyl group Chemical group [H]N([H])C(C(=O)O*)C([H])([H])C1=C([H])N([H])C([H])=N1 0.000 claims 5
- 108020004459 Small interfering RNA Proteins 0.000 claims 3
- 230000000692 anti-sense effect Effects 0.000 claims 3
- 238000001514 detection method Methods 0.000 claims 3
- 230000000694 effects Effects 0.000 claims 3
- 239000012634 fragment Substances 0.000 claims 3
- 108091070501 miRNA Proteins 0.000 claims 3
- 239000002679 microRNA Substances 0.000 claims 3
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 claims 3
- 125000001493 tyrosinyl group Chemical group [H]OC1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 claims 3
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims 2
- 108091023037 Aptamer Proteins 0.000 claims 2
- 108020003215 DNA Probes Proteins 0.000 claims 2
- 239000003298 DNA probe Substances 0.000 claims 2
- 210000000170 cell membrane Anatomy 0.000 claims 2
- 238000001727 in vivo Methods 0.000 claims 2
- 239000002777 nucleoside Substances 0.000 claims 2
- 125000003835 nucleoside group Chemical group 0.000 claims 2
- 108090000623 proteins and genes Proteins 0.000 claims 2
- 102000004169 proteins and genes Human genes 0.000 claims 2
- 230000002285 radioactive effect Effects 0.000 claims 2
- 150000003384 small molecules Chemical class 0.000 claims 2
- 108020001019 DNA Primers Proteins 0.000 claims 1
- 239000003155 DNA primer Substances 0.000 claims 1
- 230000004913 activation Effects 0.000 claims 1
- 210000004369 blood Anatomy 0.000 claims 1
- 239000008280 blood Substances 0.000 claims 1
- 210000000845 cartilage Anatomy 0.000 claims 1
- 210000004027 cell Anatomy 0.000 claims 1
- 210000002615 epidermis Anatomy 0.000 claims 1
- 210000000981 epithelium Anatomy 0.000 claims 1
- 239000012530 fluid Substances 0.000 claims 1
- 210000003097 mucus Anatomy 0.000 claims 1
- 210000003205 muscle Anatomy 0.000 claims 1
- 210000001331 nose Anatomy 0.000 claims 1
- 239000002243 precursor Substances 0.000 claims 1
- 210000003296 saliva Anatomy 0.000 claims 1
- 238000012163 sequencing technique Methods 0.000 claims 1
- 210000003491 skin Anatomy 0.000 claims 1
- 210000001138 tear Anatomy 0.000 claims 1
- 210000001519 tissue Anatomy 0.000 claims 1
- 210000002105 tongue Anatomy 0.000 claims 1
- 210000000515 tooth Anatomy 0.000 claims 1
- 210000001635 urinary tract Anatomy 0.000 claims 1
- 210000002700 urine Anatomy 0.000 claims 1
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US62936304P | 2004-11-18 | 2004-11-18 | |
| US64947905P | 2005-02-02 | 2005-02-02 | |
| US67234605P | 2005-04-18 | 2005-04-18 | |
| PCT/US2005/041664 WO2006062716A2 (en) | 2004-11-18 | 2005-11-18 | Methods and compositions for treating ocular disorders |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012000185A Division JP2012080900A (ja) | 2004-11-18 | 2012-01-04 | 視覚障害を処置するための方法および組成物 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2008520242A JP2008520242A (ja) | 2008-06-19 |
| JP2008520242A5 true JP2008520242A5 (enExample) | 2009-01-22 |
Family
ID=36578383
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007543226A Withdrawn JP2008520242A (ja) | 2004-11-18 | 2005-11-18 | 視覚障害を処置するための方法および組成物 |
| JP2012000185A Pending JP2012080900A (ja) | 2004-11-18 | 2012-01-04 | 視覚障害を処置するための方法および組成物 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012000185A Pending JP2012080900A (ja) | 2004-11-18 | 2012-01-04 | 視覚障害を処置するための方法および組成物 |
Country Status (14)
| Country | Link |
|---|---|
| US (3) | US20090017029A1 (enExample) |
| EP (1) | EP1836312B1 (enExample) |
| JP (2) | JP2008520242A (enExample) |
| KR (1) | KR101290621B1 (enExample) |
| CN (2) | CN101142321B (enExample) |
| AT (1) | ATE528410T1 (enExample) |
| AU (1) | AU2005314461B2 (enExample) |
| BR (1) | BRPI0518289A2 (enExample) |
| CA (1) | CA2588270A1 (enExample) |
| CY (1) | CY1112579T1 (enExample) |
| DK (1) | DK1836312T3 (enExample) |
| ES (1) | ES2375490T3 (enExample) |
| IL (1) | IL183284A (enExample) |
| WO (1) | WO2006062716A2 (enExample) |
Families Citing this family (66)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE426043T1 (de) | 2002-11-25 | 2009-04-15 | Sequenom Inc | Verfahren zur identifizierung des brustkrebsrisikos |
| DK1713503T3 (da) | 2004-02-10 | 2013-11-04 | Univ Colorado Regents | Hæmning af faktor b, den alternative komplemenpathway og dertil relaterede fremgangsmåde |
| EP2357257B1 (en) | 2005-02-14 | 2019-07-31 | University of Iowa Research Foundation | Methods and reagents for treatment and diagnosis of age-related macular degeneration |
| ES2548700T3 (es) | 2005-05-26 | 2015-10-20 | The Regents Of The University Of Colorado, A Body Corporate | Inhibición de la vía alternativa del complemento para el tratamiento de lesión cerebral traumática, lesión de médula espinal y afecciones relacionadas |
| US8168584B2 (en) | 2005-10-08 | 2012-05-01 | Potentia Pharmaceuticals, Inc. | Methods of treating age-related macular degeneration by compstatin and analogs thereof |
| ES2551202T5 (es) | 2005-11-04 | 2018-11-30 | Genentech, Inc. | Uso de inhibidores de la vía del complemento para tratar enfermedades oculares |
| WO2007120975A2 (en) * | 2006-02-13 | 2007-10-25 | The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Variants in complement regulatory genes predict age-related macular degeneration |
| US8012683B2 (en) | 2006-02-13 | 2011-09-06 | University Of Iowa Research Foundation | Variants in complement regulatory genes predict age-related macular degeneration |
| JP5290772B2 (ja) * | 2006-02-13 | 2013-09-18 | ユニバーシティー オブ アイオワ リサーチ ファウンデーション | 補体調節遺伝子における変異体が加齢性黄斑変性症を予測する |
| AU2007261315B2 (en) | 2006-06-21 | 2012-10-25 | Musc Foundation For Research Development | Targeting complement factor H for treatment of diseases |
| NZ574046A (en) * | 2006-07-13 | 2012-09-28 | Univ Iowa Res Found | Methods and reagents for treatment and diagnosis of vascular disorders and age-related macular degeneration |
| AU2016204271B2 (en) * | 2006-07-13 | 2018-04-19 | University Of Iowa Research Foundation | Methods and reagents for the treatment and diagnosis of vascular disorders and age-related macular degeneration |
| MX2009000909A (es) * | 2006-07-26 | 2009-02-04 | Univ Yale | Diagnostico y tratamiento de degeneracion macular relacionada con la edad. |
| CN101173314B (zh) * | 2006-10-18 | 2010-12-01 | 四川省医学科学院（四川省人民医院） | 检测老年黄斑变性疾病的试剂盒 |
| CN106084054A (zh) | 2006-11-02 | 2016-11-09 | 健泰科生物技术公司 | 人源化的抗‑d因子抗体 |
| GB0701213D0 (en) * | 2007-01-23 | 2007-02-28 | Univ Cardiff | Factor H polymorphisms in the diagnosis and therapy of inflammatory diseases such as age-related macular degeneration |
| WO2008103299A2 (en) | 2007-02-16 | 2008-08-28 | Massachusetts Eye & Ear Infirmary | Methods and compositions for prognosing, detecting, and treating age-related macular degeneration |
| AU2008251943B2 (en) | 2007-03-14 | 2013-09-05 | Alexion Pharmaceuticals, Inc. | Humaneered anti-factor B antibody |
| JP5226256B2 (ja) * | 2007-07-26 | 2013-07-03 | ニプロ株式会社 | 加齢黄斑変性症の発症リスクの予測方法 |
| CA2704809A1 (en) * | 2007-11-01 | 2009-05-07 | University Of Iowa Research Foundation | Rca locus analysis to assess susceptibility to amd and mpgnii |
| US8114592B2 (en) | 2008-03-18 | 2012-02-14 | Cambridge Enterprise Limited | Genetic markers associated with age-related macular degeneration, methods of detection and uses thereof |
| US20110190221A1 (en) * | 2008-03-28 | 2011-08-04 | Apellis Ag | Modulation and repletion/enhancement of the complement system for treatment of trauma |
| CR20170001A (es) | 2008-04-28 | 2017-08-10 | Genentech Inc | Anticuerpos anti factor d humanizados |
| CN103333952B (zh) * | 2008-11-05 | 2015-07-29 | 健泰科生物技术公司 | 年龄相关的黄斑变性中的遗传多态性 |
| US20120115925A1 (en) * | 2008-12-23 | 2012-05-10 | Massachusetts Eye And Ear Infirmary | Allelic Variants Associated with Advanced Age-Related Macular Degeneration |
| KR100937720B1 (ko) * | 2009-04-20 | 2010-01-20 | 전남대학교산학협력단 | ＣＦＨ 또는 ＡｐｏＨ를 급성골수성백혈병 관해 진단용 생화학적 마커로 사용하는 방법 |
| AU2010266127B2 (en) | 2009-07-02 | 2015-11-05 | Musc Foundation For Research Development | Methods of stimulating liver regeneration |
| EA201290286A1 (ru) | 2009-11-05 | 2013-01-30 | Алексион Кембридж Корпорейшн | Лечение пароксизмальной ночной гемоглобинурии, гемолитических анемий и патологических состояний с вовлечением внутрисосудистого и внесосудистого гемолиза |
| EP2533797A1 (en) | 2010-02-12 | 2012-12-19 | CeMM Forschungszentrum für Molekulare Medizin GmbH | Complement factor h for oxidative stress disease conditions |
| SG185483A1 (en) | 2010-05-14 | 2012-12-28 | Univ Colorado Regents | Improved complement receptor 2 (cr2) targeting groups |
| US8809517B2 (en) * | 2010-06-01 | 2014-08-19 | University Of Kentucky Research Foundation | Method of inhibiting Alu RNA and therapeutic uses thereof |
| EP2585110A4 (en) | 2010-06-22 | 2014-01-22 | Univ Colorado Regents | ANTIBODIES AGAINST THE C3D FRAGMENT OF THE COMPLEMENT COMPONENT 3 |
| WO2011163394A2 (en) | 2010-06-22 | 2011-12-29 | Apellis Pharmaceuticals, Inc. | Compstatin analogs for treatment of neuropathic pain |
| JP2014502953A (ja) | 2010-08-16 | 2014-02-06 | ザ トラスティース オブ コロンビア ユニバーシティ イン ザ シティ オブ ニューヨーク | 細胞透過性治療薬の鼻腔内送達 |
| FR2983212A1 (fr) * | 2011-11-28 | 2013-05-31 | Lfb Biotechnologies | Aptameres anti-fh, procede pour leur obtention et utilisations |
| FR2988298A1 (fr) * | 2012-03-23 | 2013-09-27 | Lfb Biotechnologies | Facteur h pour son utilisation comme molecule antioxydante |
| US9803005B2 (en) | 2012-05-24 | 2017-10-31 | Alexion Pharmaceuticals, Inc. | Humaneered anti-factor B antibody |
| CN102707068B (zh) * | 2012-05-31 | 2015-03-18 | 北京大学 | 补体h因子用作甲基苯丙胺成瘾患者的基因表达产物中的应用 |
| AU2013302441B2 (en) | 2012-08-17 | 2018-05-10 | The Regents Of The University Of Colorado, A Body Corporate | Compositions and methods for detecting complement activation |
| US10413620B2 (en) | 2012-08-17 | 2019-09-17 | The Regents Of The University Of Colorado, A Body Corporate | Light-emitting versions of the monoclonal antibody to C3D (MAB 3D29) for imaging |
| CA2891673C (en) | 2012-11-15 | 2025-10-07 | Apellis Pharmaceuticals Inc | Cell-reactive, long-acting, or targeted compstatin analogs and related compositions and methods |
| JP5721150B2 (ja) * | 2013-03-14 | 2015-05-20 | 学校法人 埼玉医科大学 | 加齢黄斑変性症の発症リスクの予測方法 |
| PL2968457T3 (pl) | 2013-03-14 | 2018-12-31 | Baxalta Incorporated | Czynnik h do transplantacji |
| JP6484215B2 (ja) | 2013-03-14 | 2019-03-13 | バクスアルタ インコーポレイテッド | 関節リウマチの治療のためのｈ因子 |
| WO2014152391A1 (en) | 2013-03-15 | 2014-09-25 | Apellis Pharmaceuticals, Inc. | Cell-penetrating compstatin analogs and uses thereof |
| AU2013202965B2 (en) | 2013-03-15 | 2016-07-21 | Takeda Pharmaceutical Company Limited | Improved method for producing factor h from a plasma precipitation fraction |
| CR20160132A (es) | 2013-08-12 | 2016-08-25 | Genentech Inc | Composiciones y método para tratar condiciones asociadas con el complemento |
| US20150093331A1 (en) * | 2013-10-01 | 2015-04-02 | OncoLock Co., Ltd. | Biomarkers for breast cancer |
| KR102131973B1 (ko) * | 2013-12-30 | 2020-07-08 | 주식회사 케이티 | 개인 건강관리 방법 및 시스템 |
| HUE050921T2 (hu) * | 2014-02-26 | 2021-01-28 | Allergan Inc | C5 komplementkomponens antitestek |
| US10155983B2 (en) | 2014-03-31 | 2018-12-18 | Machaon Diagnostics, Inc. | Method of diagnosis of complement-mediated thrombotic microangiopathies |
| SG11201608868PA (en) | 2014-05-01 | 2016-11-29 | Genentech Inc | Anti-factor d antibody variants and uses thereof |
| KR102314785B1 (ko) * | 2015-04-21 | 2021-10-19 | 인제대학교 산학협력단 | 신규한 황반변성 진단용 마커 및 황반변성 진단방법 |
| JP6968787B2 (ja) | 2015-10-07 | 2021-11-17 | アペリス・ファーマシューティカルズ・インコーポレイテッドApellis Pharmaceuticals, Inc. | 投与レジメン |
| EP3368090A1 (en) | 2015-10-30 | 2018-09-05 | H. Hoffnabb-La Roche Ag | Anti-factor d antibody variant conjugates and uses thereof |
| EP3368074A2 (en) | 2015-10-30 | 2018-09-05 | Hoffmann-La Roche AG | Anti-factor d antibodies and conjugates |
| CN106018838A (zh) * | 2015-11-01 | 2016-10-12 | 李倩 | 一种用于检测眼科疾病的试剂盒及其检测方法 |
| CN114712497B (zh) * | 2015-12-03 | 2024-03-22 | 雷杰纳荣制药公司 | 抗vegf剂在制备用于治疗新生血管性年龄相关性黄斑变性患者的药物中的用途 |
| KR102011182B1 (ko) * | 2016-10-07 | 2019-08-16 | 단국대학교 천안캠퍼스 산학협력단 | 익상편 과발현 유전자 및 이의 용도 |
| US11040107B2 (en) | 2017-04-07 | 2021-06-22 | Apellis Pharmaceuticals, Inc. | Dosing regimens and related compositions and methods |
| KR20240167712A (ko) | 2017-12-15 | 2024-11-27 | 아펠리스 파마슈티컬스 인코포레이티드 | 투여 요법 및 관련 조성물 및 방법 |
| US11519020B2 (en) | 2018-05-25 | 2022-12-06 | Regeneron Pharmaceuticals, Inc. | Methods of associating genetic variants with a clinical outcome in patients suffering from age-related macular degeneration treated with anti-VEGF |
| EP3824095A4 (en) * | 2018-07-20 | 2022-04-20 | University of Utah Research Foundation | GENE THERAPY FOR MACULATE GENERATION |
| US20220146530A1 (en) * | 2019-03-07 | 2022-05-12 | Reti Mark Co., Ltd. | A combination of biomarkers for diagnosing of age-related macular degeneration and use thereof |
| KR102333953B1 (ko) * | 2020-07-10 | 2021-12-02 | 인제대학교 산학협력단 | 신규한 황반변성 진단용 유전자 마커 |
| CN113293206A (zh) * | 2021-07-23 | 2021-08-24 | 西安医臻生物医药科技有限公司 | 一种快速鉴别老年黄斑病变风险的方法及应用 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA1284931C (en) * | 1986-03-13 | 1991-06-18 | Henry A. Erlich | Process for detecting specific nucleotide variations and genetic polymorphisms present in nucleic acids |
| NZ509797A (en) * | 1998-07-10 | 2003-11-28 | Univ Sydney | Prophylactic treatments of neovascularisation in macular degeneration using a steroid |
| WO2001066800A2 (en) * | 2000-03-07 | 2001-09-13 | Whitehead Institute For Biomedical Research | Human single nucleotide polymorphisms |
| EP2026073B1 (en) * | 2000-04-29 | 2016-03-30 | University Of Iowa Research Foundation | Diagnostics and therapeutics for macular degeneration-related disorders |
| CN1466953A (zh) * | 2003-01-15 | 2004-01-14 | 哈佛东方生物医药（云南）有限公司 | 预防治疗老年黄斑变性的复合制剂 |
| EP2357257B1 (en) * | 2005-02-14 | 2019-07-31 | University of Iowa Research Foundation | Methods and reagents for treatment and diagnosis of age-related macular degeneration |
-
2005
- 2005-11-18 WO PCT/US2005/041664 patent/WO2006062716A2/en not_active Ceased
- 2005-11-18 CN CN2005800467319A patent/CN101142321B/zh not_active Expired - Fee Related
- 2005-11-18 EP EP05851755A patent/EP1836312B1/en not_active Expired - Lifetime
- 2005-11-18 AT AT05851755T patent/ATE528410T1/de active
- 2005-11-18 BR BRPI0518289-1A patent/BRPI0518289A2/pt not_active IP Right Cessation
- 2005-11-18 DK DK05851755.8T patent/DK1836312T3/da active
- 2005-11-18 US US11/791,025 patent/US20090017029A1/en not_active Abandoned
- 2005-11-18 CN CN2012100868621A patent/CN102618644A/zh active Pending
- 2005-11-18 JP JP2007543226A patent/JP2008520242A/ja not_active Withdrawn
- 2005-11-18 ES ES05851755T patent/ES2375490T3/es not_active Expired - Lifetime
- 2005-11-18 CA CA002588270A patent/CA2588270A1/en not_active Abandoned
- 2005-11-18 AU AU2005314461A patent/AU2005314461B2/en not_active Ceased
- 2005-11-18 KR KR1020077013736A patent/KR101290621B1/ko not_active Expired - Fee Related
-
2007
- 2007-05-17 IL IL183284A patent/IL183284A/en not_active IP Right Cessation
-
2011
- 2011-09-16 US US13/235,289 patent/US20120135000A1/en not_active Abandoned
-
2012
- 2012-01-04 JP JP2012000185A patent/JP2012080900A/ja active Pending
- 2012-01-11 CY CY20121100030T patent/CY1112579T1/el unknown
-
2013
- 2013-09-26 US US14/038,602 patent/US20140018306A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2008520242A5 (enExample) | ||
| CN110791560B (zh) | 一种用于阿尔茨海默病诊断和/或治疗的miRNA标志物 | |
| JP2009502115A5 (enExample) | ||
| JP2006500949A5 (enExample) | ||
| WO2007139811A1 (en) | Methods and kits for linking polymorphic sequences to expanded repeat mutations | |
| CN106047991A (zh) | 用于检测川崎病的方法及试剂盒 | |
| SG190570A1 (en) | Antiviral therapy | |
| JP2003508022A5 (enExample) | ||
| WO2009034055A1 (en) | Method for predicting the response of a subject suffering from a viral infection of the liver to an antiviral therapy | |
| CA3116522A1 (en) | A method of detecting small rna | |
| CN106434982A (zh) | 缺血性脑卒中相关的分子标记物及其应用 | |
| CN105063194A (zh) | 一种帕金森的诊断标志物及其应用 | |
| CN111733227A (zh) | 特发性视神经炎诊断分子标记物circRNA、试剂盒及应用 | |
| CN106661618B (zh) | Dna甲基化状态作为酒精使用和戒酒的生物标志物 | |
| JPWO2020154268A5 (enExample) | ||
| CN111411152A (zh) | 人源环状rna在制备心脏疾病相关产品中的应用 | |
| JP2009523004A5 (enExample) | ||
| JP2010501162A5 (enExample) | ||
| CN109609649B (zh) | 一种用于直肠腺癌诊疗的lncRNA | |
| JP2005034151A5 (enExample) | ||
| EP3845666A1 (en) | A method of detecting small rna | |
| AU2021107694A4 (en) | A method of detecting small rna | |
| CN113881672B (zh) | 乙型肝炎病毒感染者miRNA分子标志物组合及其应用 | |
| CN108752452B (zh) | Sars及其突变体的应用 | |
| JP2012080777A (ja) | ネフローゼ症候群の検査方法、並びにネフローゼ症候群の予防又は治療薬およびそのスクリーニング方法 |